13
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T25821 |
ML359
ML-359,ML 359 |
Others | Others |
ML359 是选择性可逆的蛋白质二硫键异构酶有效抑制剂(IC50:250 nM)。它对体内血栓形成具有抑制作用。 | |||
T1893 |
Parmodulin 2
ML 161 |
Protease-activated Receptor | GPCR/G Protein |
Parmodulin 2 (ML 161) 是一种蛋白酶激活受体 1(PAR1) 变构抑制剂,IC50为 0.26 μM。它是蛋白酶激活受体 1 (PAR1) 介导的血小板活化的抑制剂,可以抑制体外血小板聚集和体内血小板血栓形成。 | |||
T0389 |
Dabigatran etexilate
达比加群酯,BIBR 1048 |
Thrombin | Proteases/Proteasome |
Dabigatran etexilate (BIBR 1048) 是一种 Dabigatran 前药,具有口服活性。它具有抗凝作用,能够预防心房颤动引起的静脉血栓栓塞和中风。 | |||
T68002L |
(R)-Naroparcil
4-[4-[(5-Thio-α-D-xylopyranosyl)thio]benzoyl]benzonitrile(Isomer-120819-70-7) |
Others | Others |
(R)-Naroparcil 是 Naroparcil 的异构体。 Naroparcil 是一种4-甲基伞形酮基 β-D-木糖苷类似物,与血管平滑肌细胞增殖有关,在 Wessler 淤滞模型中抑制血栓的形成。 | |||
T6295 |
Dabigatran
BIBR 953,BIBR 953ZW,达比加群 |
Thrombin | Proteases/Proteasome |
Dabigatran (BIBR 953ZW) 是一种口服抗凝剂,是一种可逆的,竞争性的直接凝血酶 (thrombin) 抑制剂,Ki=4.5 nM。它也抑制凝血酶诱导的血小板聚集 (IC50=10 nM)。 | |||
T31206 |
Darexaban
YM 150,Darexaban, Tanexaban,YM150 |
Factor Xa | Metabolism |
Darexaban (Tanexaban, YM-150) 是选择性的、口服具有活力的 Xa 因子 (FXa) 抑制剂,IC50=54.6 nM。它对其他相关丝氨酸蛋白酶(如胰蛋白酶、凝血酶和激肽释放酶)具有高选择性。它具有抗凝和抗血栓形成作用。 | |||
T39121 |
Odatroltide
DHDMIQK(KAP),Odatroltide |
||
Odatroltide is a nanoscale P-selectin inhibitor that serves as a nano-delivery system for 6,7-dihydroxyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and KPAK to specifically target the thrombus. | |||
T28571 |
RO 23-6152
RO 236152,RO-23-6152 |
||
RO 23-6152, a new calcium antagonist, can inhibit platelet aggregation in vitro associated with occlusive coronary thrombus formation. | |||
T70349 |
DJT06001
|
||
DJT06001 is a selective Factor Xa inhibitor, reducing thrombus formation with low risk of bleeding. | |||
T71364 |
Selatogrel
|
||
Selatogrel, also known as ACT-246475, is a reversible, selective, and potent antagonist of the platelet P2Y12 receptor. It therefore acts as a platelet aggregation inhibitor. Selatogrel dose-dependently blocks thrombus formation and displays a wide therapeutic window. | |||
T81282 |
RGDV
|
||
RGDV为血小板聚集抑制剂,能够抑制血小板依赖性血栓形成,并通过靶向效应进行肿瘤识别。 | |||
T75408 | Batroxobin | ||
Batroxobin (DF-521),一种从Bothrops atrox moojeni获得的蛇毒,能促进血栓溶解,防止血栓复发并具有神经保护作用,显示出在脑静脉血栓性疾病研究中的潜力。 | |||
T71300 |
Pentoxifylline-d6
|
||
Pentoxifylline-d6 is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent. It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 µM. Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood. It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T35624 | Ajoene | ||
Ajoene is a disulfide that has been found inA. sativumand has diverse biological activities, including antibacterial, anticancer, antiplatelet, and antioxidant properties.1,2,3,4It is active against Gram-positive (MICs = 5-160 µg/ml) and Gram-negative bacteria (MICs = 136-200 µg/ml), as well as yeasts (MICs = 10-20 µg/ml).1Ajoene is cytotoxic to mouse melanoma cells (IC50= 18 µM), as well as human colon, lung, mammary, and pancreatic cancer cells (IC50s = 7-41 µM).2It reduces... |